CJC-1295 No DAC Research: Body Recomp Considerations for Wholesale Buyers

CJC-1295 without DAC is a growth-hormone-releasing hormone (GHRH) analog studied in a research setting for short-duration signaling at the pituitary. Body composition — lean tissue and adipose tissue changes — appears in the GH-axis literature as a measured endpoint, not as an outcome any supplier is in a position to promise. For a business buyer, the considerations that actually affect your decision are narrower and more concrete: is the purity independently verifiable, is testing done per batch, is the certificate of analysis tied to the lot you received, and does your catalog language stay inside research-use-only framing. All compounds discussed here are research use only and are not for human consumption.

What removing the DAC actually changes about the molecule

The "DAC" in CJC-1295 refers to a drug affinity complex — a chemical moiety added to the peptide so it binds covalently to serum albumin after entering circulation. That binding is what extends the molecule's presence in the bloodstream in published pharmacokinetic work. Strip the DAC off and you are left with the modified GHRH fragment on its own, with a far shorter circulating window.

That difference is the entire reason two versions exist. Research suggests the endogenous GH axis operates in pulses rather than at a steady state, and investigators studying pulsatile signaling generally want an agent whose exposure profile rises and clears rather than one that sustains. The no-DAC form is the version used when the research model calls for a short, discrete signal at the pituitary somatotrophs. The DAC form is used when sustained receptor exposure is the variable under study. Neither is "stronger" — they answer different mechanistic questions.

This also explains why the no-DAC version shows up so often in the same literature as ghrelin-receptor agonists. Mechanistic studies frequently examine GHRH analogs alongside growth hormone secretagogues because the two act through separate receptor pathways, and researchers designing comparative work want both available. For a catalog buyer, that's a demand signal, not a protocol: the two categories move together because the research questions overlap. Real Peptides does not publish combination guidance, dosing, or administration instructions for any compound, and no legitimate research supplier should.

Why body recomposition is a research endpoint, not a selling point

This is the single most important distinction for a business that resells. Body composition outcomes — changes in lean mass, changes in fat mass, changes in markers along the GH/IGF-1 axis — are things investigators measure. Studies report varied and context-dependent findings depending on the model, the species, the exposure design, and the endpoint chosen. "Research suggests" and "studies indicate" are the honest verbs here, and they are the only verbs that belong in your own copy.

What happens in practice is that a reseller reads a mechanistic summary, compresses it into a benefit statement, and puts that statement on a product page. At that point the description is no longer about the compound science — it is a claim about what the product does for a person. Whether that crosses a regulatory line is not a question a supplier can answer for you, and it is not a question this article can settle. It is a question for your own attorney and, if you hold a professional license, for your state board.

The practical discipline is simple and worth building into your content workflow: describe what research examines, never what a customer will experience. Keep "research use only" and "not for human consumption" on the label, the product page, and the invoice. Audit your existing catalog copy for outcome verbs that crept in during a rush. Buyers who take this seriously tend to have fewer uncomfortable conversations later, and they tend to be the partners suppliers can work with at volume.

Where this compound fits in a wholesale catalog

CJC-1295 no DAC is a growth-factor and signaling compound, and it tends to be stocked by businesses whose research customers are already buying in that category. Catalog planning here is less about any single SKU and more about coherence — a buyer ordering a GHRH analog is usually also sourcing secretagogues, tissue-signaling compounds, and metabolic-pathway research items. Breadth within a category generally does more for order size than breadth across unrelated categories, though how that plays out depends entirely on your customer base and volume.

A few operational points matter more than they first appear:

Format and stability. The compound is supplied as a lyophilized powder in a sealed vial. Lyophilized peptides are generally more stable in storage than solutions, which is why the research supply chain is built around powder. Storage conditions vary by compound and by supplier guidance — ask for written handling and storage instructions in the datasheet rather than assuming a standard.

Concentration is the ceiling of what a supplier should tell you. Real Peptides publishes vial content in milligrams. Any guidance past that — preparation steps, volumes, units, or anything resembling an administration instruction — is not something a research-use-only supplier provides, and a supplier that volunteers it is telling you something about how it views its own compliance posture.

Label integrity through the chain. If you relabel or repackage, the research-use-only designation and lot traceability have to survive the process. A lot number that cannot be matched back to a certificate of analysis is a lot you cannot defend if a customer asks a hard question.

What to verify before ordering any GHRH analog at volume

The supplier evaluation questions below are the ones that actually separate serious operations from drop-shippers. Ask them in writing, before the first order, and keep the answers.

The pattern to watch for is unverifiable verification — the claim of testing without the artifact of testing. A purity percentage with no chromatogram behind it is a number, not evidence. A certificate with no lot number is a template. Treat the document trail as the product feature it is, because when your own customer asks how you know what is in the vial, the document trail is your entire answer.

Compliance questions that belong with your own counsel

This section is informational and is not legal advice. Nothing here describes what any jurisdiction permits or forbids.

Research-compound resale sits in a regulatory space that varies by state, by license type, and by business model, and the honest answer for a general-audience article is that the questions matter more than any answer written by someone who does not know your situation. The questions worth putting in front of an attorney, and where relevant your state licensing board, generally include: how does your board view research-use-only inventory held by your type of entity; what labeling and recordkeeping obligations attach to you as a reseller rather than as an end user; what does your professional liability carrier say about carrying these items; who in the chain is treated as the responsible party for a given lot; and if you operate across state lines, which state's framework governs which part of the transaction.

A second set of questions is contractual rather than regulatory: what happens to a shipment damaged in transit, how are lot recalls handled, what documentation will you receive if a customer disputes contents, and what are the terms if a batch fails testing after it has left the supplier. Suppliers that have thought about these scenarios can answer them immediately. That responsiveness is itself diligence data.

What Real Peptides does differently

Real Peptides operates on the principle that a wholesale buyer should be able to check the claims rather than accept them.

Purity at 99%+, by HPLC. Every compound in the catalog is held to a 99%+ HPLC purity standard, with the analytical method named rather than implied.

Seven-panel testing, per batch. Testing is run on each production batch — not once on a founding lot and reused indefinitely. Batch-level testing is what makes a lot number meaningful.

Publicly verifiable COAs. Certificates of analysis are published and viewable. A prospective partner can examine the lab results before applying, without submitting a request, paying a document fee, or taking a sales representative's word for it. This is the deliberate opposite of the common industry pattern where COAs are gated, sold separately, or produced only after an order is placed.

US fulfillment in 5–7 days. Orders ship domestically and arrive within a 5–7 day window, which is what makes inventory planning possible without holding excess stock against unpredictable transit.

A three-step wholesale application. The Wholesale Partner Program uses a three-step application. Pricing tiers are disclosed to approved partners rather than hidden behind indefinite quote cycles.

None of this is a claim about research outcomes or about what any compound does. It is a claim about the supply chain — which is the part of the transaction a supplier is actually accountable for.

If you are evaluating a supplier now

If you are a med spa, clinic, telehealth company, wellness business, or reseller building a catalog and your evaluation has reached the point of comparing documentation rather than marketing, the Wholesale Partner Program application is the next step. Review the published COAs first, confirm that the purity and batch-testing standards match what you need to be able to tell your own customers, and apply once the paperwork satisfies you.

The CJC-1295 No DAC 10mg listing sits alongside related research compounds including Ipamorelin 10mg, Tesamorelin 10mg, and AOD-9604, and buyers planning category depth can review the broader Growth Factor & Tissue Signaling Research and Mitochondrial & Metabolic Pathway Research collections, or start from the Popular Peptides range.